louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03604796: Alternative Paracetamol Treatments for the Neonate With a hsPDA
Official title: Alternative Acetaminophen Treatment of the Hemodynamivally Significant Patent Ductus Arteriosus in Preterm Neonates Who Are Not Candidates for Enteral Administration: A Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Ductus Arteriosus, Patent
Keywords: acetaminophen
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2018-07-30
Enrollment: 80
Sex: ALL
Minimum age (years): 2
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Early targeted treatment of a hemodynamically significant patent ductus arteriosus (hsPDA) during the first week of life in preterm neonates is often recommended. Our standard first line therapeutic approach is enteral acetaminophen. However many extremely low birth weight infants may be on limited or no feeds when PDA closure is determined to be indicated, thus restricting the use of enteral acetaminophen. Several studies have suggested that intravenous acetaminophen is less effective than enteral. Thus, in this study, we propose to compare two alternative modes of administration when enteral acetaminophen is not an option.

Detailed description: Once parental consent for entrance into the study is obtained, eligible babies will be randomized to receive either IV acetaminophen (perfalgen) by continuous infusion at 2.5 mg/kg/h following a loading dose of 15 mg /kg/ over 20 minutes or rectal acetaminophen at 15 mg/kg every 6 hours for a period of 3 days.

Eligibility criteria: Inclusion Criteria:

Inborn preterm neonates, \< 1000 gm birth weight; \< 28 weeks' gestational age; who are admitted to the neonatal intensive care unit of the Shaare Zedek Medical Center and are diagnosed with a hemodynamically significant patent ductus arteriosus within the first week of life and who are on limited or no enteral feeds -

Exclusion Criteria:

Other congenital heart disease, major congenital anomalies, sepsis; and/or NEC.

Primary outcomes:
measure: Ductal closure
timeFrame: Up to 1 week following treatment
Secondary outcomes:
measure: PDA Ligation
timeFrame: Completion of study intervention until 40 weeks post-conception
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Neonatal Intensive Care Unit - Shaare Zedek Medical Center
Study officials:
affiliation: Shaare Zedek Medical Center
name: Cathy Hammerman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00722696: Metabolic Effects of Eccentric Endurance Training
Official title: Metabolic Effects of Eccentric Endurance Training
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Metabolism
Keywords: Metabolism
Muscles
Exercise
Lead sponsor: Vorarlberg Institute for Vascular Investigation and Treatment
Sponsor class: OTHER
First posted: 2008-07-25
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to evaluate metabolic parameters in previously sedentary individuals before and after eccentric endurance training (hiking downwards). Study participants will regularly hike downwards over a difference in altitude of 540 meters during 8 weeks. For the opposite way, a cable car will be used. Metabolic profiles will be obtained at baseline and after the 8 weeks period of eccentric endurance exercise.


Eligibility criteria: Inclusion Criteria:

* men and women
* age over 18 years

Exclusion Criteria:

* previous systematic endurance training (\>3 times per week \>30 min)
* body mass index \> 35 kg/m²
* heavy smoking (\>20 cigarettes per day)
* regular alcohol consumption \>60g per day
* history of cardiovascular disease
* established musculoskeletal disease
* unwillingness to stay in the area for the whole period

Primary outcomes:
measure: Change in metabolic parameters during 8 weeks of hiking downwards
timeFrame: 8 weeks
Secondary outcomes:
measure: Change in muscle strength during 8 weeks of hiking downwards
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Feldkirch
country: Austria
facility: Vorarlberg Institute of Vascular Investigation and Treatment
state: Vorarlberg
Study officials:
affiliation: Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT-Institute)
name: Heinz Drexel, Prof, MD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04926558: TROMS (Trainee Reported Outcome Measurement): the New Era of Surgical Evaluation
Official title: TROMS (Trainee Reported Outcome Measurement): the New Era of Surgical Evaluation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Surgical Procedure, Unspecified
Keywords: TROMS
PROMS
surgical assessment
learning curve
OSATS
MIR
Lead sponsor: Hospital del Mar
Sponsor class: OTHER
First posted: 2021-06-15
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all surgical residents of HMar

Brief summary: TROMS (trainee reported outcome assessment): assessment of surgical training of residents in general surgery


Eligibility criteria: Inclusion criteria:

All surgical residents in the department of general and digestive surgery

Exclusion criteria:

Not applicable

Primary outcomes:
measure: Assessment of surgical skills achieved by residents
timeFrame: 5 years
Secondary outcomes:
measure: Trainee reported outcomes measurements
timeFrame: 5 years
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Parc de Salut Mar de Barcelona- Hospital del Mar
state: Cataluña
Study officials:
References:
Clinical trial NCT02465658: Risk Factors for Co-existence of Cervical Elongation in Uterine Prolapse
Official title: Risk Factors for Co-existence of Cervical Elongation in Uterine Prolapse
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pelvic Organ Prolapse
Keywords: uterine prolapse
cervical elongation
pelvic floor reconstruction surgery
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2015-06-08
Enrollment: 300
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with uterine prolapse and underwent vaginal total hysterectomy

Brief summary: The presence of co-existence of cervical elongation in women of uterine prolapse may decrease the patients' satisfaction of uterine-preservation surgery for uterine prolapse, and additional surgery, such as Manchester surgery, may be needed to solve the problem.Thus the aim of this study is to investigate the risk factors of co-existence of cervical elongation in uterine prolapse.

Detailed description: Purpose:

Thus the aim of this study is to investigate the risk factors of co-existence of cervical elongation in uterine prolapse.

Patients and Methods:

Between January 1994 and October 2014, all women underwent vaginal total hysterectomy in a medical center were enrolled in this study. Medical records were reviewed. Cervical elongation is defined as the presence of cervical length \>3.38 cm or cervix to corpus ratio \>0.79.

Expected Results:

The investigators will get the risk factors of co-existence of cervical elongation in uterine prolapse, and the result should be helpful for preoperative consultation, especially for uterine-preserving pelvic floor reconstruction surgery.

Eligibility criteria: Inclusion Criteria:

* All women with uterine prolapse underwent vaginal total hysterectomy
* \> 20 years old.

Exclusion Criteria:

* nil

Primary outcomes:
measure: Factors associated with coexistent cervical elongation in cases with uterine prolapse
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Department of Obstetrics & Gynecology, National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT02010996: Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass
Official title: Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass - a Randomized Control Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Bypass Graft Stenosis of Autologous Vein
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
First posted: 2013-12-13
Enrollment: 72
Sex: ALL
Minimum age (years): 10
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The great saphenous vein is the most commonly used material in coronary vascular bridging operation. Coronary bypass operation to obtain the great saphenous vein is mainly through the incision open groin to ankle. This operation may damage the lymphatic, cause lymph circumfluence obstacle, cause fat liquefaction, scar formation, wound dehiscence, around hematoma and other a series of symptoms.Based on some studies and our experience that vacuum assisted closure （VAC）is effective in complex wound failures following Stripping saphenous vein, we use VAC to prevent seroma formation after Stripping saphenous vein in Coronary bypass. This study is aimed to evaluate the efficacy and economics benefits of early VAC application on postoperative complications and wound healing after Stripping saphenous vein in Coronary bypass in comparison to conventional suction drain.


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Coronary heart disease patients to transplant more than 2 vascular bridge
* The thigh groin following from the saphenous vein

Exclusion Criteria:

* Subjects does not agree to participate in clinical trials
* Subjects had a injury, operation history of Thigh
* Subjects having ever received chemotherapy before the surgery
* Subjects with known hypersensitivity to components of the surgical sticky membrane

Primary outcomes:
measure: Early Complications of Vascular Zone
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Changhai Hospital
state: Shanghai
Study officials:
affiliation: Changhai Hospital
name: hongda bi, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yu Y, Song Z, Xu Z, Ye X, Xue C, Li J, Bi H. Bilayered negative-pressure wound therapy preventing leg incision morbidity in coronary artery bypass graft patients: A randomized controlled trial. Medicine (Baltimore). 2017 Jan;96(3):e5925. doi: 10.1097/MD.0000000000005925.
Clinical trial NCT04337996: Dynamic Evaluation of COVID-19 Diagnostic Tests
Official title: Dynamic Evaluation of COVID-19 Diagnostic Tests
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Lead sponsor: Tourcoing Hospital
Sponsor class: OTHER
First posted: 2020-04-08
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Rapid antigenic tests are not yet used in real life. Their contribution in the diagnostic strategy based on the gold standard including anamnesis, thoracic CT and PCR has not been evaluated.

We propose to compare to the Gold-Standard defined above, the combination of an SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.

Detailed description: This is an interventional study comparing gold standard anamnesis, thoracic CT and PCR versus SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.

Patients will be sampled for the tests at Day 1 and then monitored for symptoms and clinical data and additional test at Day 21.

Eligibility criteria: Inclusion Criteria:

* Symptomatic patient with confirmed Gold-Standard SARS-CoV-2 (COVID-19) infection
* Presenting at least one criterion for hospitalization:

  * Respiratory failure and oxygenation
  * Circulatory failure (systolic BP \< 90 mmHg)
  * Neurological failure (confusion, drowsiness, altered consciousness)
  * Polypathological terrain and co-morbidities (chronic respiratory failure, heart failure or cardiovascular pathology, renal failure, diabetes, immunosuppression, obesity, cirrhosis)
* Eligible for different sampling methods
* Beneficiary of a social insurance scheme or entitled person

Exclusion Criteria:

* Gold Standard not in favour of SARS-Cov-2 infection (COVID 19)
* Minor patient
* Refusal to participate
* Patient under guardianship
* Patient under guardianship
* Pregnant or breastfeeding woman

Primary outcomes:
measure: Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies
timeFrame: day 1
Secondary outcomes:
measure: Positive or negative Covid-19 test
timeFrame: day 1
measure: Positive or negative character of the antibodies test
timeFrame: day 1
measure: Positive or negative character of the antibodies test
timeFrame: day 21
measure: Biological parameters
timeFrame: day 1
measure: Biological parameters
timeFrame: Day 21
measure: medical-economic comparison
timeFrame: day 1
Other outcomes:
Locations:
city: Tourcoing
country: France
facility: CH Tourcoing
Study officials:
affiliation: CH TOURCOING
name: Pierre PATOZ, PharmD
role: PRINCIPAL_INVESTIGATOR
affiliation: CH TOURCOING
name: Barthelemy LAFONDESMURS, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00354796: The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin
Official title: The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With Enoxaparin
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Coronary Syndrome
Venous Thromboembolism
Atrial Fibrillation
Hypercoagulability
Keywords: bleeding
anticoagulation
LMWH
Enoxaparin
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2006-07-20
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients admitted to tertiary hospital

Brief summary: We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.

Detailed description: Patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. Clinical efficacy as well as adverse events will be monitored.

Eligibility criteria: Inclusion Criteria:

* treatment with enoxaparin

Exclusion Criteria:

* no

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah University Hospital
name: Mordechai Muszkat, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05195996: Beta Blocker Effects in Traumatic Brain Injury
Official title: Beta Blocker Effects on Patients With Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Trauma, Brain
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2022-01-19
Enrollment: 40
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study will be conducted on polytrauma patient who are admitted from emergency room or postoperative with head trauma to evaluate effects of beta blocker on patients with TBI.

Detailed description: The study will be conducted on polytrauma patient who are admitted from emergency room or postoperative with head trauma . Patients will be randomly assigned into two groups by sealed envelope technique into two equal groups.

Parameters assessment:

* Length of ICU stay
* Length of total hospital stay
* CT scan to exclude another intracranial hemorrhage or increase in hemorrhage
* Functional status will be assessed using the GCS
* Hemodynamic data ( bl.p / hr )
* Crystalloid volume that patient need in 24h
* Mortality rate

Eligibility criteria: Inclusion Criteria:

* GCS preoperative \>10
* Abbreviated Injury Scale (AIS) \>3
* Length stay in ICU \>48 h

Exclusion Criteria:

* Hypersensitivity to propranolol
* Asthmatic patient
* COPD
* History of smoking
* Any cardiac problems eg: ( heart failure or HB )
* pheochromocytoma
* Pregnant patient
* Length stay \<48h
* Death within 48 h of admission
* Patient who previously received any beta blocker at home.
* Symptomatic Bradycardia \<60 b/m (sick sinus syndrome)
* Hemodynamic unstable patients

Primary outcomes:
measure: survival
timeFrame: 7 days
Secondary outcomes:
measure: heart rate
timeFrame: 7 days
measure: icu stay
timeFrame: 7 days
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Faculty of Medicine, University Hospitals
state: Menoufia
Study officials:
affiliation: Menoufia University
name: mostafa f mansour, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06614296: Unscheduled Hospital Readmission After Crenel Lateral Interbody Fusion
Official title: Factors and Experiences Associated with Unscheduled Hospital Readmission After Crenel Lateral Interbody Fusion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spine Degeneration
Keywords: Spine Degeneration
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2024-09-26
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients (\&gt;18 years old) with spinal degeneration undergoing CLIF surgery, including both unscheduled and scheduled readmissions.

Brief summary: The goal of this observational study is to learn about the readmission related to Crenel Lateral Interbody Fusion (CLIF). The main question it aims to answer is:

What are the risk factors for readmission after CLIF surgery?


Eligibility criteria: Inclusion Criteria:

* Patients with spinal degeneration undergoing CLIF surgery

Exclusion Criteria:

* Under the age of 18

Primary outcomes:
measure: Unscheduled readmission
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: 2nd Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT06789796: a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
Official title: A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Small-cell Lung Cancer
Lead sponsor: Qilu Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-01-23
Enrollment: 636
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after concurrent or sequential chemoradiotherapy.

QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.


Eligibility criteria: Inclusion Criteria:

* The patient must be aged between 18 and 75 years (inclusive of boundary values), and both males and females are eligible.
* Pathologically confirmed LS-SCLC \[I-III stage SCLC (any T, any N, M0)\], according to the American Joint Committee on Cancer (AJCC, 8th edition) staging manual.
* Received 4 cycles of chemotherapy concurrent or sequential with radiotherapy. Chemotherapy must contain platinum and etoposide. Radiotherapy must be either total 60-70 Gy over 6 weeks for the QD regimen or total 45 Gy over 3 weeks for BID schedules.
* Patients must have achieved a complete response (CR), partial response (PR), or stable disease (SD) after receiving curative platinum-based CRT and must not have developed progressive disease (PD) prior to study entry.

Exclusion Criteria:

* Mixed SCLC and non-small cell lung cancer (NSCLC).
* Extensive-stage SCLC.
* Active or prior documented autoimmune or inflammatory disorders.
* Received other chemotherapy regimens besides etoposide and platinum-based therapy.
* Active or prior documented autoimmune or inflammatory disorders.
* Presence of interstitial lung disease or active non-infectious pneumonia (excluding grade 1 radiation pneumonitis not treated with corticosteroids).

Primary outcomes:
measure: Progression-free survival (PFS)
timeFrame: up to 2 years
measure: Overall survival (OS)
timeFrame: up to 5 years
Secondary outcomes:
measure: objective response rate (ORR)
timeFrame: up to 2 years
measure: disease control rate (DCR)
timeFrame: up to 2 years
measure: duration of response (DoR)
timeFrame: up to 2 years
measure: PFS
timeFrame: up to 2 years
measure: 1-year OS rate
timeFrame: up to 1 year
measure: 2-year OS rate
timeFrame: up to 2 years
measure: adverse events
timeFrame: up to 2 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03395496: Comparison of Biodentine and MTA Pulpotomies in the Primary Molar Teeth 3 Year Follow up
Official title: Comparison of Biodentine and MTA Pulpotomies in the Primary Molar Teeth 3 Year Follow up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Pulpotomy
Dental Caries
Keywords: pulpotomy
pediatric dentistry
primary molars
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2018-01-10
Enrollment: 200
Sex: ALL
Minimum age (years): 7
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare two pulpotomy medicaments in primary molars clinically.A total of 200 primary molars with deep caries were treated with two different pulpotomy medicaments (Mineral Trioxide Aggregate and BiodentineTM) in this study. The inclusion criteria for tooth selection were no clinical and radiographic evidence of pulp pathology. During 36 months of follow-up at 3-month intervals, clinical and radiographic success and failures were recorded.


Eligibility criteria: Inclusion Criteria:

* no clinical and radiographic evidence of pulp pathology,
* no clinical and radiographic symptoms,
* no history of spontaneous pain and tenderness,
* no percussion, swelling or sinus tracts and pathologic mobility.

Exclusion Criteria:

* any clinical or radiographic evidence of pulp degeneration (spontaneous or nocturnal tooth pain, tenderness to percussion, pathological mobility, internal or external root resorption, swelling or fistula, widened periodontal ligament (PDL)
* furcal or periapical radiolucency teeth requiring more than 5 minutes to achieve hemostasis during clinical procedure.
* without permanent successor

Primary outcomes:
measure: Total success rate
timeFrame: 12 months after pulpotomy treatment
Secondary outcomes:
measure: Total success rate
timeFrame: 24 months after pulpotomy treatment
Other outcomes:
measure: Total success rate
timeFrame: 36 months after pulpotomy treatment
Locations:
city: Istanbul
country: Turkey
facility: Istanbul University
Study officials:
References: